TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36897226

Group type: EXPERIMENTAL
Intervention: Tablet-based contraception education intervention
Number of subjects: 25
Study: 36897239

Group type: EXPERIMENTAL
Intervention: vPatch (active group)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Sham device (control group)
Number of subjects: 59
Study: 36897251

Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cell therapy combined with autologous CD19+ feeding T cells (FTCs) and tyrosine kinase inhibitor (TKI) as consolidation therapy.
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: CD19 CAR T-cell therapy combined with autologous CD19+ feeding T cells (FTCs) and TKI as consolidation therapy.
Number of subjects: 13
Study: 36897310

Group type: EXPERIMENTAL
Intervention: Endometriosis treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Migraine treatment
Number of subjects: 0
Study: 36897413

Group type: EXPERIMENTAL
Intervention: faricimab 6.0 mg every 8 weeks (Q8W)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: faricimab 6.0 mg per personalized treatment interval (PTI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: aflibercept 2.0 mg every 8 weeks (Q8W)
Number of subjects: 60
Study: 36897427

Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Docetaxel
Number of subjects: 0
Study: 36897458

Group type: EXPERIMENTAL
Intervention: Adenoviral vectors
Number of subjects: 204
Study: 36897464

Group type: EXPERIMENTAL
Intervention: Robot-assisted rehabilitation (RR) for 60 min, 5 days a week, for 6 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Conventional rehabilitation (CR) with individualized upper-limb rehabilitation
Number of subjects: 41
Study: 36897535

Group type: EXPERIMENTAL
Intervention: Perceptive rehabilitation
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Mobilization
Number of subjects: 55

Group type: COMPARATOR
Intervention: Control
Number of subjects: 55
Study: 36897544

Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Vonoprazan 20 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg
Number of subjects: 16
Study: 36897592

Group type: EXPERIMENTAL
Intervention: 50% discount on eligible fruits and vegetables
Number of subjects: 2744

Group type: EXPERIMENTAL
Intervention: Prefilled shopping carts with tailored fruit and vegetable items (default options)
Number of subjects: 2744

Group type: EXPERIMENTAL
Intervention: Combination of discount and default options
Number of subjects: 2744

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 2744

Group type: EXPERIMENTAL
Intervention: Discount condition
Number of subjects: 2744

Group type: EXPERIMENTAL
Intervention: Default condition
Number of subjects: 2744

Group type: EXPERIMENTAL
Intervention: Combination condition
Number of subjects: 2744

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 2744
Study: 36897642

Group type: EXPERIMENTAL
Intervention: Activity tracker
Number of subjects: 30

Group type: COMPARATOR
Intervention: SWOT analysis
Number of subjects: 30
Study: 36897745

Group type: EXPERIMENTAL
Intervention: Cardiovascular magnetic resonance (CMR) left atrioventricular coupling index (LACI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rest and ergometer-stress CMR
Number of subjects: 0
Study: 36897799

Group type: EXPERIMENTAL
Intervention: Ultra-processed diet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unprocessed diet
Number of subjects: 20
Study: 36897803

Group type: EXPERIMENTAL
Intervention: Iterative Metal Artifact Reduction (IMAR)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard kernel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sharp kernel
Number of subjects: 50

Group type: COMPARATOR
Intervention: Virtual Monoenergetic Imaging (VMI) levels >70 keV
Number of subjects: 50
Study: 36897834

Group type: EXPERIMENTAL
Intervention: Dulaglutide
Number of subjects: 1669

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1669
Study: 36897863

Group type: EXPERIMENTAL
Intervention: Robot-assisted therapy (RAT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Virtual reality (VR)-based neuromotor rehabilitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Robotic and VR devices
Number of subjects: 0
Study: 36897877

Group type: EXPERIMENTAL
Intervention: Community-wide mass drug administration (cMDA) for soil-transmitted helminths (STH)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Existing infrastructure from other NTD programs like lymphatic filariasis (LF)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Engagement of local leaders and community groups
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Integration of cMDA with immunization, maternal child health, and non-communicable disease control programs
Number of subjects: 3
Study: 36898078

Group type: EXPERIMENTAL
Intervention: Axitinib and Avelumab
Number of subjects: 40
Study: 36898233

Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg/day for 1 year
Number of subjects: 2840

Group type: COMPARATOR
Intervention: Placebo for 1 year
Number of subjects: 2840
Study: 36898269

Group type: EXPERIMENTAL
Intervention: Xerosis cutis
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Intertrigo
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Incontinence-associated dermatitis
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Skin tears
Number of subjects: 314

Group type: EXPERIMENTAL
Intervention: Pressure ulcers
Number of subjects: 314
Study: 36898292

Group type: EXPERIMENTAL
Intervention: Cisplatin-paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topotecan-paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cisplatin-paclitaxel-bevacizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topotecan-paclitaxel-bevacizumab
Number of subjects: 0
Study: 36898363

Group type: EXPERIMENTAL
Intervention: SMARTCare intervention (online SM education program I-Can Manage + 5 sessions of telephone cancer coaching)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care control group
Number of subjects: 62
Study: 36898361

Group type: COMPARATOR
Intervention: Usual care arm of the GAP70+ trial
Number of subjects: 369
Study: 36898393

Group type: EXPERIMENTAL
Intervention: Nexvax2 (non-homozygous group)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo (non-homozygous group)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Nexvax2 (homozygous group)
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo (homozygous group)
Number of subjects: 179

Group type: EXPERIMENTAL
Intervention: Nexvax2
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study: 36898391

Group type: EXPERIMENTAL
Intervention: Vaccinated patients (booster and two doses)
Number of subjects: 1909

Group type: COMPARATOR
Intervention: Unvaccinated patients
Number of subjects: 1909

Group type: COMPARATOR
Intervention: Pre-vaccination phase
Number of subjects: 1909

Group type: COMPARATOR
Intervention: Alpha-delta phase
Number of subjects: 1909

Group type: COMPARATOR
Intervention: Omicron phase
Number of subjects: 1909
Study: 36898400

Group type: EXPERIMENTAL
Intervention: Aerosolised Ad5-nCoV
Number of subjects: 356

Group type: EXPERIMENTAL
Intervention: Intramuscular Ad5-nCoV
Number of subjects: 356

Group type: COMPARATOR
Intervention: CoronaVac
Number of subjects: 356
Study: 36898606

Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Literature comparison condition
Number of subjects: 244
Study: 36898607

Group type: EXPERIMENTAL
Intervention: MFG facilitated by parent peers (MFG-PP)
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: MFG facilitated by community health workers (MFG-CHW)
Number of subjects: 636

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: MFG-PP and MFG-CHW
Number of subjects: 636
Study: 36898748

Group type: EXPERIMENTAL
Intervention: Cefepime
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Piperacillin-tazobactam
Number of subjects: 2500
Study: 36898751

Group type: EXPERIMENTAL
Intervention: 7-day course of hydrocortisone and fludrocortisone
Number of subjects: 1800

Group type: EXPERIMENTAL
Intervention: 10-day standard course of dexamethasone
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Fludrocortisone
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Placebo for hydrocortisone and fludrocortisone
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Placebo for dexamethasone
Number of subjects: 1800
Study: 36898758

Group type: EXPERIMENTAL
Intervention: Cerebral autoregulation using PRx (Pressure Reactivity Index)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Cerebral perfusion pressure measurements
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Fluctuations in measured parameters
Number of subjects: 135
Study: 36898767

Group type: EXPERIMENTAL
Intervention: Additional elastic band exercise
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual exercise-based care
Number of subjects: 200
Study: 36898933

Group type: EXPERIMENTAL
Intervention: Immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chimeric antigen receptor T-cell therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oncolytic virotherapy
Number of subjects: 0
Study: 36898939

Group type: EXPERIMENTAL
Intervention: QFR-based virtual PCI
Number of subjects: 300

Group type: COMPARATOR
Intervention: Angiography-based PCI (standard of care)
Number of subjects: 300
Study: 36898948

Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focal therapy/ablation treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy and immunotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Histopathologic changes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Novel therapies
Number of subjects: 0
Study: 36898949

Group type: EXPERIMENTAL
Intervention: Using Peer Support to Aid in Prevention and Treatment in Prediabetes
Number of subjects: 355

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 355
Study: 36899125

Group type: EXPERIMENTAL
Intervention: MenACYW-TT booster vaccination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: MenACYW-TT booster vaccination with co-administration of MenB vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: MCV4-CRM-primed participants receiving MenACYW-TT alone
Number of subjects: 0
Study: 36899292

Group type: EXPERIMENTAL
Intervention: Upfront open surgical necrosectomy
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Endoscopic drainage of pancreatic necrosis
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Enteral nutrition
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: History of uncontrolled arterial hypertension
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: qSOFA
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Renal failure
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Haemodynamic failure
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Cholangitis
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Abdominal compartment syndrome
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Gastrointestinal/intra-abdominal bleeding
Number of subjects: 247
Study: 36899310

Group type: EXPERIMENTAL
Intervention: Noninvasive myocardial work (MW) parameters during isovolumic relaxation (IVR)
Number of subjects: 448

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 448
Study: 36899317

Group type: EXPERIMENTAL
Intervention: Sedentary bouts of 1-to-10 minutes (mean 95.1, SD 25.0)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Sedentary bouts of >10-to-30 minutes (mean 13.3, SD 3.4)
Number of subjects: 460

Group type: EXPERIMENTAL
Intervention: Sedentary bouts of >30 minutes (mean 3.5, SD 1.9)
Number of subjects: 460
Study: 36899351

Group type: EXPERIMENTAL
Intervention: Structured educational intervention involving lower limb physical exercise and daily ambulation guidelines
Number of subjects: 224

Group type: COMPARATOR
Intervention: Standard treatment in primary care (cleansing, debridement, healing in a moist environment, multilayer compression therapy)
Number of subjects: 224
Study: 36899369

Group type: EXPERIMENTAL
Intervention: Olmesartan 20 mg once daily
Number of subjects: 80

Group type: COMPARATOR
Intervention: Amlodipine 5 mg once daily
Number of subjects: 80
Study: 36899430

Group type: EXPERIMENTAL
Intervention: Silymarin 700mg + 8mg vitamin E + 50mg phosphatidylcholine daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Maltodextrin 700mg + 8mg vitamin E + 50mg phosphatidylcholine daily (Control)
Number of subjects: 0
Study: 36900181

Group type: EXPERIMENTAL
Intervention: Azacitidine treatment
Number of subjects: 272
Study: 36900279

Group type: EXPERIMENTAL
Intervention: Segmental Abutting Esophagus-Sparing (SAES) radiotherapy (45 Gy in 3 Gy daily fractions over 3 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-Segmental Abutting Esophagus-Sparing (non-SAES) radiotherapy
Number of subjects: 30
Study: 36900554

Group type: EXPERIMENTAL
Intervention: Ginger extract (100 mL, 0.2 g/100 mL)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Oral glucose tolerance test (200 mL)
Number of subjects: 24
Study: 36900802

Group type: EXPERIMENTAL
Intervention: Road Cycling (RC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Mountain Biking (MTB)
Number of subjects: 40
Study: 36900811

Group type: EXPERIMENTAL
Intervention: Support from a physiotherapist (PT) with higher follow-up frequency and aerobic physical fitness tests
Number of subjects: 190

Group type: COMPARATOR
Intervention: Continued physical activity on prescription at a healthcare center (HCC)
Number of subjects: 190
Study: 36900872

Group type: EXPERIMENTAL
Intervention: Digitally supported approach for early screening of frailty risk factors using the SUNFRAIL questionnaire and in-depth scale tests.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SUNFRAIL questionnaire administered by seven centers.
Number of subjects: 100
Study: 36901227

Group type: EXPERIMENTAL
Intervention: Active VeNS
Number of subjects: 66

Group type: COMPARATOR
Intervention: Sham VeNS
Number of subjects: 66
Study: 36901671

Group type: EXPERIMENTAL
Intervention: Self-chosen music intervention
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 82
Study: 36902139

Group type: EXPERIMENTAL
Intervention: BCL-2 inhibitors (specific drugs not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PD-1/PD-L1 pathway inhibitors (specific drugs not detailed)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: S63845, S64315, chidamide, arsenic trioxide (ATO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knockdown of the PD-L1 gene
Number of subjects: 0
Study: 36902217

Group type: EXPERIMENTAL
Intervention: MRD-directed therapy, specific drugs and dosages not mentioned, duration not mentioned
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment without MRD-directed therapy, specific drugs and dosages not mentioned, duration not mentioned
Number of subjects: 0
Study: 36902536

Group type: EXPERIMENTAL
Intervention: Point-of-Care Ultrasonography (POCUS) assessment
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard care (non-POCUS)
Number of subjects: 36
Study: 36902798

Group type: EXPERIMENTAL
Intervention: Androgen deprivation plus stereotactic radiation to all metastatic sites and radium223
Number of subjects: 38

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: PET imaging (PSMA or fluciclovine PET)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Additional imaging or tumor board adjudication
Number of subjects: 38
Study: 36902861

Group type: EXPERIMENTAL
Intervention: Non-operative treatment (closed reduction and dorsal casting for 5 weeks) for displaced DRFs
Number of subjects: 50

Group type: COMPARATOR
Intervention: Non-operative treatment (closed reduction and dorsal casting for 5 weeks) for minimally or non-displaced DRFs
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Non-operative treatment (closed reduction and dorsal casting for 5 weeks) for both groups
Number of subjects: 50
Study: 36904212

Group type: EXPERIMENTAL
Intervention: Zinc and micronutrients intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 36904237

Group type: EXPERIMENTAL
Intervention: Non-nutritive sweetened beverages (NSBs)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Water
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Ectopic Fat sub-study (intrahepatocellular lipid by 1H-MRS)
Number of subjects: 80
Study: 36904251

Group type: EXPERIMENTAL
Intervention: Walnut supplementation (15% of daily energy)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (walnut-free diet)
Number of subjects: 0
Study: 36905131

Group type: EXPERIMENTAL
Intervention: Aerobic exercise for 48 weeks
Number of subjects: 84

Group type: COMPARATOR
Intervention: Active control (health education)
Number of subjects: 84
Study: 36905161

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (E-Stim) on both gastrocnemius muscles for 1 hour daily for 4 weeks
Number of subjects: 18

Group type: COMPARATOR
Intervention: Nonfunctional electrical stimulation device (Control group)
Number of subjects: 18
Study: 36905177

Group type: EXPERIMENTAL
Intervention: Wilms' tumor 1 expression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Genetic mutations
Number of subjects: 0
Study: 36905198

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Moderate-to-Vigorous Intensity Continuous Training (MICT)
Number of subjects: 38
Study: 36905248

Group type: EXPERIMENTAL
Intervention: Intensive glucose control
Number of subjects: 10251

Group type: COMPARATOR
Intervention: Standard glucose control
Number of subjects: 10251
Study: 36905347

Group type: EXPERIMENTAL
Intervention: Mean arterial pressure (MAP) ranging between 65 mmHg and 120 mmHg during anesthesia and surgery
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MAP lower than 65 mmHg
Number of subjects: 100
Study: 36905390

Group type: EXPERIMENTAL
Intervention: Vaginal progesterone
Number of subjects: 300

Group type: COMPARATOR
Intervention: Cervical pessary
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Cervical pessary and vaginal progesterone
Number of subjects: 300
Study: 36905419

Group type: EXPERIMENTAL
Intervention: Spatial training in virtual reality
Number of subjects: 17

Group type: COMPARATOR
Intervention: Non-Spatial control training
Number of subjects: 17
Study: 36905441

Group type: EXPERIMENTAL
Intervention: Telemedicine group (measured and transmitted home BP readings)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Usual care group (face-to-face consultations)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Telemedicine group
Number of subjects: 49
Study: 36905458

Group type: EXPERIMENTAL
Intervention: Plant-based diet adherence
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Healthful plant-based dietary index
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Unhealthful plant-based dietary index
Number of subjects: 658

Group type: EXPERIMENTAL
Intervention: Fish consumption (≥0.93 portion/week)
Number of subjects: 658
Study: 36905485

Group type: EXPERIMENTAL
Intervention: Insulin degludec
Number of subjects: 419

Group type: COMPARATOR
Intervention: Insulin glargine U100
Number of subjects: 419
Study: 36905498

Group type: EXPERIMENTAL
Intervention: TV-46000 (subcutaneous LAI antipsychotic agent)
Number of subjects: 63
Study: 36905528

Group type: EXPERIMENTAL
Intervention: Adalimumab immunogenicity assessed using electrochemiluminescence (ECL) and enzyme-linked immunosorbent (ELISA) assays.
Number of subjects: 1459

Group type: EXPERIMENTAL
Intervention: Titer-based classification with lower limit of quantitation (LLOQ) as threshold.
Number of subjects: 1459

Group type: EXPERIMENTAL
Intervention: Stepwise population pharmacokinetic (popPK) modeling.
Number of subjects: 1459

Group type: EXPERIMENTAL
Intervention: ELISA assay for immunogenicity.
Number of subjects: 1459
Study: 36905632

Group type: EXPERIMENTAL
Intervention: Driving practice for older drivers with MCI
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normal cognition (NC) drivers
Number of subjects: 12
Study: 36905719

Group type: EXPERIMENTAL
Intervention: Mevidalen 10 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mevidalen 30 mg
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Mevidalen 75 mg
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 36905736

Group type: EXPERIMENTAL
Intervention: Oxytocin administration
Number of subjects: 87
Study: 36905771

Group type: EXPERIMENTAL
Intervention: Fulvestrant (500 mg on days 0, 14 and 28, then every 28 ± 3 days, n = 77)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Exemestane (25 mg/day, n = 67)
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 145

Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 145
Study: 36905980

Group type: EXPERIMENTAL
Intervention: CC + ECIG retraining
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: CC only retraining
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham retraining
Number of subjects: 90
Study: 36906081

Group type: EXPERIMENTAL
Intervention: Polysaccharide hemostatic powder (PHP) with diluted epinephrine injection and powder application as spray
Number of subjects: 216

Group type: COMPARATOR
Intervention: Conventional endoscopic treatment (electrical coagulation or hemoclipping after diluted epinephrine injection)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 216
Study: 36906262

Group type: EXPERIMENTAL
Intervention: Patient-reported triggers (median number 8, interquartile range 5-10)
Number of subjects: 2793

Group type: EXPERIMENTAL
Intervention: Each additional trigger reported
Number of subjects: 2793

Group type: EXPERIMENTAL
Intervention: Trigger number
Number of subjects: 2793
Study: 36906345

Group type: EXPERIMENTAL
Intervention: BPZE1-BPZE1
Number of subjects: 280

Group type: COMPARATOR
Intervention: BPZE1-placebo
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: Tdap-BPZE1
Number of subjects: 280

Group type: COMPARATOR
Intervention: Tdap-placebo
Number of subjects: 280